Skip to main navigation
Skip to search
Skip to main content
University of Birmingham Home
Help & FAQ
Home
Research output
Profiles
Research units
Projects
Activities
Datasets
Equipment
Prizes
Press/Media
Search by expertise, name or affiliation
Ximelagatran for stroke prevention in atrial fibrillation
Christopher Boos,
Gregory Lip
Birmingham Medical School
Cardiovascular Sciences
Research output
:
Contribution to journal
›
Article
5
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Ximelagatran for stroke prevention in atrial fibrillation'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Active Compounds
25%
Anticoagulation
25%
Anticoagulation Monitoring
25%
AstraZeneca
25%
Atrial Fibrillation
100%
Clinical Practice
25%
Daily Dose
25%
Drug Interactions
25%
Embolic Event
25%
Embolic Stroke
25%
Highly Effective
25%
Liver Enzymes
25%
Low Potential
25%
Melagatran
25%
Non-inferiority
25%
Non-valvular Atrial Fibrillation
25%
Oral Absorption
25%
Oral Anticoagulants
25%
Oral Direct Thrombin Inhibitor
50%
Potential Problems
25%
Routine Clinical Practice
25%
Safety Data
25%
Stroke Event
25%
Stroke Prevention
50%
Stroke Prevention in Atrial Fibrillation
100%
Therapeutic Anticoagulation
25%
Twice Daily
25%
Ventricular Arrhythmia
25%
Vitamin K Antagonists
25%
Warfarin
100%
Warfarin Therapy
25%
Ximelagatran
100%
Pharmacology, Toxicology and Pharmaceutical Science
Anticoagulant Agent
16%
Antivitamin K
16%
Atrial Fibrillation
100%
Cerebrovascular Accident
100%
Drug Interaction
16%
Heart Arrhythmia
16%
Liver Enzyme
16%
Melagatran
16%
Thrombin Inhibitor
33%
Thromboembolism
16%
Warfarin
83%
Ximelagatran
100%